Safety and Efficacy Study of Umbilical Mesenchymal Stem Cells for Liver Cirrhosis
Launched by ALLIANCELLS BIOSCIENCE CORPORATION LIMITED · Apr 9, 2012
Trial Information
Current as of July 24, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • written informed consent
- • aged 30-60 years
- • clinical diagnosis of compensated or decompensated liver
- • child-Pugh B/C (7-12 points)
- • expecting lifetime is over three years
- Exclusion Criteria:
- • pregnant woman
- • patient with severe vascular diseases
- • patient with any organ failure
- • patient with any tumors
- • patient with HIV
- • patient who has been transplanted
- • patient treated with immunosuppressors
- • patient for whom the follow-up is considered impossible
- • patients with any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the subject
About Alliancells Bioscience Corporation Limited
Alliancells Bioscience Corporation Limited is a pioneering clinical trial sponsor dedicated to advancing innovative biopharmaceutical solutions. With a focus on developing cutting-edge therapies, the company leverages its expertise in biomedical research and regulatory compliance to facilitate the efficient design and execution of clinical trials. Committed to improving patient outcomes, Alliancells collaborates with leading healthcare institutions and researchers to bring transformative treatments to market, ensuring adherence to the highest standards of safety and efficacy. Through its comprehensive approach, Alliancells aims to contribute significantly to the evolving landscape of biotechnology and healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lianyungang, Jiangsu, China
Beijing, Beijing, China
Lanzhou, Gansu, China
Qionghai, Hainan, China
Shanghai, Shanghai, China
Xi'an, Shanxi, China
Patients applied
Trial Officials
Xuetao Pei, MD,PhD
Study Chair
Chinese Industry and Innovative Technology Strategic Alliance of Stem Cells and Regenerative Medicine
Yongjun Liu, MD,PhD
Study Director
Alliancells Bioscience Corporation Limited
Mingyuan Wu, MD,PhD
Study Director
Eastern Union Stem Cell & Gene Engineering Co.,Ltd， Alliancells Bioscience Corporation Limited
Hanwei Li, MD,PhD
Principal Investigator
The 302 Hospital of Chinese People's Liberation Army
Liming Wang, MD
Principal Investigator
The 323 Hospital of Chinese People's Liberation Army
Xun Li, MD,PhD
Principal Investigator
LanZhou University
Liming Chen, MD,PhD
Principal Investigator
ongji Hospital of Tongji University
Jianwei Lu, MD
Principal Investigator
Tongji Hospital
Hui Shi, MD
Principal Investigator
The First People's Hospital of Lianyungang
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials